NutriBand Inc.: management transactions · United States · SEC (Form 4)

About NutriBand Inc.

Nutriband Inc. is a U.S.-listed healthcare and pharmaceutical company traded on the NASDAQ in the United States. For investors, the company is best understood as a specialized transdermal drug-delivery developer with a strong focus on abuse-deterrent pharmaceutical technologies, especially in the context of the opioid crisis. Nutriband was incorporated in Nevada on January 4, 2016, and its operational headquarters are in Orlando, Florida. At this stage, the company is primarily a development-stage innovator rather than a broad commercial pharmaceutical platform. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1676047/000121390026049399/ea0287168-10k_nutriband.htm?utm_source=openai)) The core investment case centers on AVERSA™, Nutriband’s transdermal technology platform designed to improve the safety profile of skin-delivered medicines, particularly fentanyl-based patch products. The company also works on broader transdermal pharmaceutical development through its clinical subsidiary 4P Therapeutics. In addition, Nutriband says it has revenue-generating subsidiaries, including Pocono Pharmaceutical, which focuses on contract manufacturing, and Active Intelligence, which is associated with sports recovery products. This gives the group a mixed profile that combines R&D, contract services, and early-stage commercial activity. ([nutriband.com](https://www.nutriband.com/?utm_source=openai)) Competitively, Nutriband operates in a niche but potentially attractive segment of the pharmaceutical industry: higher-value transdermal systems where differentiation depends on intellectual property, clinical evidence, regulatory progress, and the ability to secure industrial partners. The company’s strategic positioning is tied to abuse-deterrent solutions, a theme that can resonate with investors looking at specialty pharma and drug-delivery innovation. That said, the risk profile remains elevated because monetization still depends heavily on clinical, regulatory, and commercial execution. ([nasdaq.com](https://www.nasdaq.com/press-release/nutriband-unveils-groundbreaking-innovation-in-transdermal-medications-2023-09-20-0?utm_source=openai)) Recent developments reinforce the company’s pipeline-driven profile. In 2025, Nutriband said it received final meeting minutes from a U.S. FDA meeting regarding AVERSA™ FENTANYL, with the aim of supporting an IND submission for a Human Abuse Potential clinical study. Earlier disclosures also highlighted the issuance of a U.S. patent for AVERSA™ Technology and referenced commercial projections for its lead product. From an equity research perspective, Nutriband remains a NASDAQ-listed U.S. micro-cap story with identifiable regulatory catalysts, but limited visibility until more clinical and commercial milestones are achieved. ([nasdaq.com](https://www.nasdaq.com/press-release/nutriband-announces-successful-meeting-completed-united-states-fda-its-abuse?utm_source=openai))